Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Goding lab working in collaboration with the University Rey Juan Carlos show that fatty acid uptake activates an AXL-CAV1-β-catenin axis to drive melanoma invasiveness.

Cancer progression and non-genetic therapy resistance are driven by interactions between the tumour microenvironment and cancer cell plasticity. Phenotype-specific expression of the AXL receptor tyrosine kinase is key in cancer invasion and resistance to treatment, but how the ALX is activated has remained unclear.

Using melanoma as a model, the Goding research group and collaborators at University Rey Juan Carlos show that AXL is activated by exposure to human adipocytes and to oleic acid, a fatty acid abundant in lymph and adipocytes. The activation of AXL triggers formation and translocation of a β-catenin-CAV1 complex required for melanoma invasiveness.

Of particular note, only undifferentiated, high in AXL melanoma cells engage in symbiosis with human adipocytes, leading to AXL-dependent fatty acid uptake and nuclear localisation of the β-catenin-CAV1 complex. These results demonstrate an AXL and CAV-1 dependent mechanism by which a nutritional input drives phenotype-specific activation of a pro-metastasis program.

Given the key role of AXL in a wide range of cancers, the results offer major insights into the mechanisms of cancer cell dormancy and therapy resistance.

To read more, please see the full article in Genes & Development